Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic

MLA

Ilse Bader, et al. “Rationale and Design of the BeyeOMARKER Study: Prospective Evaluation of Blood- and Eye-Based Biomarkers for Early Detection of Alzheimer’s Disease Pathology in the Eye Clinic.” Alzheimer’s Research & Therapy, vol. 16, no. 1, Aug. 2024, pp. 1–18. EBSCOhost, https://doi.org/10.1186/s13195-024-01545-1.

APA

Ilse Bader, Colin Groot, H. Stevie Tan, Jean-Marie A. Milongo, Jurre den Haan, Inge M. W. Verberk, Keir Yong, Julie Orellina, Shannon Campbell, David Wilson, Argonde C. van Harten, Pauline H. B. Kok, Wiesje M. van der Flier, Yolande A. L. Pijnenburg, Frederik Barkhof, Elsmarieke van de Giessen, Charlotte E. Teunissen, Femke H. Bouwman, & Rik Ossenkoppele. (2024). Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic. Alzheimer’s Research & Therapy, 16(1), 1–18. https://doi.org/10.1186/s13195-024-01545-1

Chicago

Ilse Bader, Colin Groot, H. Stevie Tan, Jean-Marie A. Milongo, Jurre den Haan, Inge M. W. Verberk, Keir Yong, et al. 2024. “Rationale and Design of the BeyeOMARKER Study: Prospective Evaluation of Blood- and Eye-Based Biomarkers for Early Detection of Alzheimer’s Disease Pathology in the Eye Clinic.” Alzheimer’s Research & Therapy 16 (1): 1–18. doi:10.1186/s13195-024-01545-1.